HAE
HaemoneticsANYSE / Health Care Equipment & Services
Last Price
At close
2026-07-22
Current thesis
The post-earnings bull read is that Haemonetics closed FY26 with better-than-feared core growth: Q4 adjusted EPS slightly beat the Zacks-based snapshot, FY27 guidance implies re-acceleration, and Hospital plus Plasma are carrying the portfolio while Vivasure adds another interventional growth leg.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.6.
What can break
Adjusted gross margin also fell 50 bps, with less favorable mix and tariff impacts called out in the earnings release [#8-K-2026-05-07].
Momentum
80
Value
65
Sentiment
43
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $66.00 · Bull $78.00 · Bear $46.00
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $86.60
Why
Momentum80 · Δ7d +15.1
Value65 · Δ7d -0.6
Sentiment43 · Δ7d -4.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
80
26% active weight
Current posture
7d trendFlat
Δ7d
+15.1
Δ21d
+0.5
Value
65
39% active weight
Current posture
7d trendFlat
Δ7d
-0.6
Δ21d
-0.5
Sentiment
43
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.4
Δ21d
-5.2
Why this grade
Composite grade A. Momentum 80.0 / Value 64.9 / Sentiment 43.3
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$3.55B
Beta
0.28
Shares Out
45.45M
P/E (TTM)
24.0
P/S (TTM)
2.89
P/FCF (TTM)
18.08
Rev YoY
+4.8%
EPS YoY
-137.2%
Gross Margin
+55.7%
Op Margin
+18.3%
Net Debt
$1.03B
Current Ratio
2.95
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology